SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
公司代码SIGA
公司名称SIGA Technologies Inc
上市日期Sep 09, 1997
CEONguyen (Diem)
员工数量46
证券类型Ordinary Share
年结日Sep 09
公司地址31 East 62Nd Street
城市NEW YORK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编10065
电话12126729100
网址https://www.siga.com/
公司代码SIGA
上市日期Sep 09, 1997
CEONguyen (Diem)